Special Issue Archive - Oncology Practice Management

Skip to main content

Latest Special Issue

Pirtobrutinib in Covalent BTKi-Treated Patients With CLL/SLL: Translating Clinical Trial Insights Into Real-World Practice

Clinical Trials to Clinical Practice

Pirtobrutinib in Covalent BTKi-Treated Patients With CLL/SLL: Translating Clinical Trial Insights Into Real-World Practice

In their expert commentaries, Jackie Broadway-Duren, PhD, DNP, APRN, FNP-BC, FAANP, and Mollie Moran, APRN-CNP, examine the noncovalent Bruton’s tyrosine kinase (BTK) inhibitor, pirtobrutinib, in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Special Issues Archive

Pirtobrutinib in Covalent BTKi-Treated Patients With CLL/SLL: Translating Clinical Trial Insights Into Real-World Practice

2026 Oncology Guide to Patient Support Services

The Evolution of Abemaciclib Clinical Trial Data for the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer

Identification and Treatment of Patients With Hormone Receptor–Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence: monarchE Study Long-Term Outcomes

Pirtobrutinib in Pretreated Patients With CLL/SLL: Applying Lessons From Clinical Trials to Clinical Practice

Best Practices in Ovarian Function Suppression in Breast Cancer

2023 Year in Review: Cholangiocarcinoma

Clinical Trials to Clinical Practice: GI Cancer Edition

Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

2022 Year in Review: Multiple Myeloma

2022 Year in Review: Cholangiocarcinoma

Faculty Perspectives: Optimizing Clinical Outcomes and Value-Based Management in Multiple Myeloma—The Role of Isatuximab

Current Approach to the Disease Journey of Patients with Relapsed or Refractory Follicular Lymphoma: Focus on the Key Manifestations, Risk Stratification, and Management Patterns

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

2022 Midyear Review: Non–Small-Cell Lung Cancer

Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management

ASK THE EXPERT: First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy

2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments

2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments

2022 Oncology Biosimilar Guide to Patient Support Services

2022 Breast Cancer Guide to Patient Support Services

Looking for more?

Browse the Digital Archive

2014 - Current

Back to Top